Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome
Guest speakers scheduled to present at the event include:
Bob Haws, M.D., Director of Clinical Research at the Marshfield Clinic Research Instituteand Director of the Center of Excellence for Bardet-Biedl Syndrome Lee Kaplan, M.D., Ph.D., Director of the Obesity, Metabolism & Nutrition Instituteat Massachusetts General Hospitaland Associate Professor of Medicine at Harvard Medical School
Additionally, Rhythm management will provide an overview of its clinical development program for setmelanotide, focusing on its combined pivotal Phase 3 trial in BBS and Alström Syndrome, which is expected to initiate and begin enrolling patients by year-end 2018.
A live audio webcast of the event will be available under “Events & Presentations” in the Investors & Media section of the Company’s website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 days following the event.
Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. Rhythm is currently evaluating the efficacy and safety of setmelanotide, the Company’s first-in-class melanocortin-4 receptor (MC4R) agonist, in Phase 3 studies in patients with pro-opiomelanocortin (POMC) deficiency obesity (which includes deficiencies in both the POMC and PCSK1 genes) and leptin receptor (LEPR) deficiency obesity. Rhythm is dedicated to improving the understanding of severe obesity that results from specific genetic disorders. For healthcare professionals, visit www.uncommonobesity.com for more information. For patients and caregivers, visit www.geneticobesity.com for more information. The company is based in
Stern Investor Relations, Inc.
Berry & Company Public Relations